Blandt 135 patienter, der gennemgik retroperitoneal og intraabdominael kirurgi (67 patienter behandlet med EVICEL og 68 i kontrolgruppen) blev ingen uønskede hændelser anset for at have en årsagssammenhæng med forsøgsbehandlingen ifølge investigators vurderinger.
Among 135 patients undergoing retroperitoneal and intra-abdominal surgery (67 patients treated with EVICEL and 68 controls), no adverse events were considered to be causally related to the study treatment according to the investigator assessments.